BMD results from pathogenic variants in the DMD gene, located on the X chromosome. The DMD gene encodes dystrophin, a structural protein essential for maintaining the integrity of muscle fiber membranes. In BMD, variants typically permit production of a reduced or partially functional dystrophin protein rather than causing near-complete absence, which accounts for the milder disease course relative to more severe dystrophinopathy phenotypes. This partial preservation of dystrophin function is a distinguishing molecular feature of BMD.

The condition follows X-linked inheritance. Penetrance is complete in males. In heterozygous females, penetrance is variable and may depend on patterns of X-chromosome inactivation. The DMD gene is located on the X chromosome.

Diagnosis of BMD is informed by clinical presentation, laboratory evaluation, molecular genetic testing, and ancillary studies. Elevated serum creatine phosphokinase (CK) concentrations are a recognized biochemical finding. Molecular genetic testing identifying pathogenic variants in the DMD gene establishes the diagnosis of a dystrophinopathy; in some cases, distinguishing BMD from more severe forms within the spectrum based on variant analysis alone may be difficult, and the clinical distinction relies in part on age of wheelchair dependency and ambulatory course.

Muscle biopsy demonstrating abnormal or reduced dystrophin protein by immunohistochemistry or Western blot supports diagnosis when molecular testing is inconclusive. Cardiac evaluation, including electrocardiography, echocardiography, and/or cardiac MRI, is part of the initial diagnostic assessment to characterize the extent of cardiac involvement. Genetic counseling is available for families in which a DMD pathogenic variant has been identified, given the X-linked inheritance pattern.

Givinostat (brand name Duvyzat), a histone deacetylase inhibitor, holds FDA orphan drug approval for the treatment of BMD and Duchenne muscular dystrophy. This represents the only FDA-approved pharmacological treatment identified in the approved records for this condition.

Cardiac complications in BMD are managed with pharmacological agents documented in the clinical literature. ACE inhibitors and/or beta blockers have been shown to improve left ventricular function when used in individuals with dystrophinopathy-related cardiomyopathy. Angiotensin II-receptor blockers such as losartan are similarly documented as effective and are used in cases of intolerance to ACE inhibitors. In cases of overt heart failure, additional agents including diuretics and digoxin are utilized. Cardiac transplantation has been performed in individuals with severe dilated cardiomyopathy and BMD in whom skeletal muscle involvement is limited.

Scoliosis management in BMD may involve bracing or surgical intervention, including spinal fusion procedures. Several additional compounds carry orphan drug designation for dystrophinopathies—including adeno-associated virus transgene of follistatin, epicatechin, and cardiosphere-derived cell therapies—and remain under clinical investigation. Botulinum toxin injections and certain anesthetic agents including succinylcholine have been documented in the clinical literature in association with adverse reactions in individuals with dystrophinopathy.

The clinical course of BMD is more favorable than the more severe end of the dystrophinopathy spectrum, with ambulatory function typically maintained into adulthood. Cardiac involvement represents the dominant driver of long-term morbidity and accounts for approximately 50% of deaths in individuals with BMD, based on documented clinical data. Dilated cardiomyopathy is the most significant life-limiting complication associated with this condition. Disease progression is generally slow following onset, though the clinical course varies considerably across individuals depending on the nature and extent of both cardiac and skeletal muscle involvement. Survival and functional outcomes are influenced by the degree of cardiac disease and the availability of cardiac management.

Active research in BMD spans gene therapy, pharmacological investigation, biomarker development, and clinical endpoint definition. Gene therapy approaches under clinical investigation focus on restoring dystrophin expression, primarily through recombinant adeno-associated virus vector systems. Clinical trials are actively recruiting participants with BMD and related dystrophinopathies, including studies specifically aimed at defining biomarkers and endpoints suited to the BMD phenotype.

A published literature base of approximately 260 classified publications in this disease area includes contributions across basic science and preclinical research, biomarker studies, and clinical trial reporting. The dominant publication type in this landscape is basic science and preclinical research. Case reports and reviews comprise a substantial portion of the published record. Multiple compounds with orphan drug designation remain in the clinical development pipeline for dystrophinopathies, including both pharmacological and cell-based investigational approaches. The sponsor landscape for active trials reflects a mix of academic medical centers and industry sponsors.